No profile data available.
Sutro Biopharma, Inc. (STRO) is a healthcare company in the additional cancer treatment drugs industry, based in South San Francisco, United States, with about 178 full-time employees.
It reported revenue of $102.48 million for fiscal year 2025, up 65.2% from fiscal year 2024, and net income of -$191.09 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $9.84 million, down 84.6% from a year before. Its market capitalization was $79.86 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Sutro Biopharma reported $102.48 million in revenue for fiscal year 2025, up 65.2% from $62.04 million in fiscal year 2024. In Q2 2026 revenue was $9.84 million.
$79.86 million as of December 4, 2025.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Context Therapeutics Inc. (CNTX), Acrivon Therapeutics, Inc. (ACRV), NeOnc Technologies Holdings, Inc. (NTHI), Instil Bio, Inc. (TIL).